INCA32459
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for INCA32459, covering 2025-11-03 to 2025-11-03. Get the full timeline:
Most recent: Clinical Trial Update: Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies [Phase 1]